Ortin Global Ltd

Ortin Laboratories, a microcap pharmaceutical company, reported negative financial results for the quarter ending March 2024. The company's PBT and PAT saw significant decreases compared to the previous year, and its operating profit was at its lowest in the last five quarters. This may raise concerns for investors and stakeholders.

Ortin Laboratories, a microcap pharmaceutical company, has hit a 52-week low on March 28, 2024, with a Strong Sell rating from MarketsMOJO. The stock has underperformed the sector by -2.88% and is trading below its moving averages. In comparison to the Sensex, the company's stock has had a negative 1-year performance, highlighting potential challenges in the competitive market. Investors should carefully evaluate the company's financial health and future prospects before making any investment decisions.

Ortin Laboratories, a microcap pharmaceutical company, has hit a 52-week low in its stock price, reaching Rs. 16.51 on March 27, 2024. MarketsMOJO has given a Strong Sell recommendation. The stock has underperformed the sector by -3.33% and has been on a downward trend for the past three days with a -7.51% decrease. It is currently trading below its moving averages and has not fared well compared to the overall market performance. The company has not made any official statements regarding its stock performance or future plans. Investors should carefully consider all factors before making any investment decisions.

Ortin Laboratories, a microcap pharmaceutical company, reported negative financial results for the quarter ending December 2023. The company's PBT, PAT, and PBDIT showed significant declines year on year, with a low EPS of -3.43. MarketsMOJO has given a 'Strong Sell' call for Ortin Labs. Investors should carefully consider all factors before making any investment decisions.

Ortin Laboratories, a microcap pharmaceutical company, reported a decline in net sales, standalone net profit, and operating profit (PBDIT) for the quarter ended September 2023. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO, with a decrease in operating profit margin and earnings per share.